Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

10.60
+0.19001.83%
Post-market: 10.690.0900+0.85%18:06 EDT
Volume:3.07M
Turnover:32.54M
Market Cap:2.13B
PE:-7.41
High:10.68
Open:10.54
Low:10.46
Close:10.41
52wk High:12.39
52wk Low:8.27
Shares:201.40M
Float Shares:195.63M
Volume Ratio:0.93
T/O Rate:1.57%
Dividend:1.00
Dividend Rate:9.43%
EPS(TTM):-1.4300
EPS(LYR):-1.4300
ROE:-8.31%
ROA:2.12%
PB:0.68
PE(LYR):-7.41

Loading ...

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

GlobeNewswire
·
Jan 26

BRIEF-Park Hotels & Resorts Inc. Announces Tax Treatment Of 2025 Dividends

Reuters
·
Jan 21

Park Hotels & Resorts Inc. Announces $1.00 Per Share 2025 Dividend Distribution

Reuters
·
Jan 21

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

GlobeNewswire
·
Jan 20

Weekly Scan of 40 New Funds: 26 Asset Managers Including Fullgoal, Penghua, ICBC Credit Suisse, ChinaAMC, and E Fund Compete with Thematic Index, FOF Stability, and Mixed Growth Offerings

Deep News
·
Jan 19

Director Christie B. Kelly Acquires Common Shares of Park Hotels & Resorts Inc

Reuters
·
Jan 17

Morgan Stanley Adjusts Price Target on Park Hotels & Resorts to $10 From $12, Maintains Equalweight Rating

MT Newswires Live
·
Jan 16

Shenzhen Company Ties Employee Weekend Schedules to Performance-Based Competition

Deep News
·
Jan 15

Park Hotels & Resorts (PK) Receives a Buy from Barclays

TIPRANKS
·
Jan 14

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

GlobeNewswire
·
Jan 12

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

GlobeNewswire
·
Jan 12

Park Hotels & Resorts Inc. announces upcoming earnings conference call

Reuters
·
Jan 09

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

GlobeNewswire
·
Jan 08

Park Hotels & Resorts Releases Annual Corporate Responsibility Report and Highlights ESG Achievements

Reuters
·
Jan 08

Park Hotels & Resorts Inc. Issues Annual Corporate Responsibility Report and Provides Update on Corporate Responsibility Achievements

THOMSON REUTERS
·
Jan 08

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

GlobeNewswire
·
Jan 07

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

GlobeNewswire
·
Jan 07

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

GlobeNewswire
·
Jan 07

Park Hotels & Resorts Initiated at Overweight by Barclays

Dow Jones
·
Jan 06

NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

GlobeNewswire
·
Jan 06